J Korean Vasc Surg Soc.  1997 Nov;13(2):203-212.

Patency Rates of Femorofemoral Bypass: Effects of Concomitant Leg Arterial Bypass

Affiliations
  • 1Department of Surgery, Kyungpook National University Hospital, Korea.

Abstract

Femorofemoral bypass was chosen as a primary(n=71) and redo (n=7) procedures for 78 patients with unilateral iliac artery occlusive disease during the period of 4 and a half years at the Department of Surgery, Kyungpook National University Hospital. The patients were categorized into 3 groups according to the patency of the superficial femoral artery on the recipient-side leg and the performance of concomitant leg arterial bypass: Group I (n=34), patent superficial femoral artery (SFA); Group II (n=19), occluded SFA left untreated; Group III (n=25), occluded SFA treated with leg arterial bypass. Adjuvant procedures during the femorofemoral bypasses included 16 femoral endarterectomies, 5 donor-side iliofemoral interposition grafts, and 4 donor-side iliac balloon angioplasties. The primary cumulative patency rates for all femorofemoral bypasses at 1, 2, 3, and 4 years were 96.3%, 84.7%, 84.7%, and 74.2%, respectively calculated by the life table method. The primary patency rates were 90.0%, 62.9%, 62.9%, 62.9% in Group II and 95.7%, 89.5%, 89.5%, 89.5% in Group III at 1, 2, 3, and 4 years after bypass grafting. The statistical analysis with log rank test to compare the patency rates between Group II and III revealed no significant (p=0.2425) differences. In summary, femorofemoral bypass was a durable bypass procedure for the patients with unilateral iliac artery occlusion. Further follow-up is required to confirm the effects of concomitant leg arterial bypass to the patency of femorofemoral bypass.

Keyword

femorofemoral bypass; Patency

MeSH Terms

Angioplasty
Endarterectomy
Femoral Artery
Follow-Up Studies
Gyeongsangbuk-do
Humans
Iliac Artery
Leg*
Life Tables
Transplants
Full Text Links
  • JKVSS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr